Postoperative Steroid Use in Adolescent Idiopathic Scoliosis and Neuromuscular Scoliosis Patients
Launched by CHILDREN'S HOSPITAL LOS ANGELES · Sep 1, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of steroids immediately after surgery for patients with adolescent idiopathic scoliosis (AIS) or neuromuscular scoliosis (NMS) who are undergoing a procedure called posterior spinal fusion (PSF). The main goal is to find out if using steroids right after surgery can help reduce the need for strong pain medications (opioids) and support patients in moving around more quickly. Researchers also want to see if taking steroids affects the healing of the surgical site and if it has any long-term effects on scar formation.
To participate in this study, patients need to be between the ages of 9 and 18 and scheduled for a PSF to treat their scoliosis. Participants will complete surveys about their pain and physical activity at the start of the study, and again at 3 months, 1 year, and 2 years after surgery. They will also have clinical photos taken of their surgical incision to assess how well it heals over time. It's important to note that some patients may not qualify due to previous surgeries or certain medical conditions. Overall, this trial aims to provide valuable information on the benefits and risks of using steroids in the recovery process after scoliosis surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Participants must meet all of the inclusion criteria to participate in this study:
- • • Patients aged 9-18 years who are scheduled to undergo posterior spinal fusion to treat AIS or NMS
- Exclusion Criteria:
- Patients will be excluded if any of the following criteria are met at baseline:
- • Prior instrumentation or spine surgery
- • Conditions associated with increased wound healing issues such as spina bifida
- • Non AIS or NMS patients
- • Not undergoing PSF
- • Outside the ages of 9-18
- • Allergies to the steroids and/or their ingredients
- • Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
- • Inability or unwillingness of individual or legal guardian/representative to give written informed consent.
About Children's Hospital Los Angeles
Children's Hospital Los Angeles (CHLA) is a renowned pediatric healthcare institution dedicated to advancing the health and well-being of children through innovative research and clinical care. As a leading clinical trial sponsor, CHLA is committed to conducting high-quality, ethical research that addresses critical pediatric health issues. With a focus on translating scientific discoveries into effective treatments, CHLA collaborates with multidisciplinary teams and leverages state-of-the-art facilities to support a wide range of clinical trials. Their mission is to enhance the understanding and treatment of childhood diseases, ultimately improving outcomes for young patients and their families.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
Lindsay Andras, MD
Principal Investigator
Children's Hospital Los Angeles
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported